We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adjusted earnings were $3.12 per share, outpacing the Zacks Consensus Estimate marginally and rising 9.9% on a year-over-year basis. Total revenues of $4 billion surpassed the consensus estimate by a slight margin and grew 2.3% from the year-ago quarter.
The IQV stock has declined 10.5% over the past six months against the 9.8% rally of the industry it belongs to and 17.4% growth of the Zacks S&P 500 Composite.
IQVIA Holdings Inc. Price, Consensus and EPS Surprise
The Research and Development segment’s revenues were $2.1 billion, increasing 1.3% from the year-ago quarter and 1% on a constant-currency basis. This metric missed our estimate of $2.2 billion and increased 9.5% on a constant-currency basis.
Revenues from the Technology and Analytics segment were $1.7 billion, growing 8.3% from the year-ago quarter and 9.5% on a constant-currency basis. The metric beat our estimate of $1.6 billion and increased 10.6% on a constant-currency basis.
Contract Sales & Medical Solutions revenues decreased 4.8% on a year-over-year basis to $177 million and increased 3.2% on a constant-currency basis. The metric missed our projection of $187 million and declined 11.1% on a constant-currency basis.
Adjusted EBITDA for the fourth quarter of 2024 was $996 million, indicating a 3.1% rise from the year-ago quarter and lagging our projection of $1 billion.
The company exited the quarter with cash and cash equivalents of $1.7 billion compared with $1.6 billion at the end of the preceding quarter. Long-term debt (less current portion) was $12.8 billion compared with $12.3 billion at the end of the third quarter of 2024.
Net cash generated from operating activities was $885 million and the capital expenditure for the quarter was $164 million. The company generated a free cash flow of $721 million in the quarter.
IQV’s 2025 Guidance
For 2025, IQVIA has raised its revenue guidance to $15.72-$16.12 billion from the preceding quarter’s view of $15.35-$15.40 billion. The mid-point ($15.92 billion) of the guided range is lower than the Zacks Consensus Estimate for revenues pegged at $16.02 billion.
The company has hiked the adjusted EPS guidance to $11.70-$12.10 from the previous quarter’s view of $11.10-$11.20. The mid-point ($11.9) of the guided range is higher than the Zacks Consensus Estimate for earnings pegged at $11.8 per share.
The company’s adjusted EBITDA view for the same period has been raised to $3.76-$3.88 billion compared with the preceding quarter’s view of $3.67-$3.70 billion.
IT’s adjusted earnings per share of $5.6 beat the Zacks Consensus Estimate by 69.3% and increased 79.3% from the year-ago quarter. Revenues of $1.7 billion surpassed the consensus estimate by 1.8% and improved 8.2% year over year.
BR’s adjusted earnings of $1.6 per share outpaced the consensus mark by 12.2% and increased 69.6% from the year-ago quarter. Total revenues of $1.6 billion surpassed the consensus mark by 3% and rose 12.8% year over year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IQVIA Earnings & Revenues Surpass Estimates in Q4, Increase Y/Y
IQVIA Holdings Analytics Inc. (IQV - Free Report) has reported impressive fourth-quarter 2024 results, wherein earnings and revenues beat the Zacks Consensus Estimate.
See Zacks Earnings Calendar to stay ahead of market-making news.
Adjusted earnings were $3.12 per share, outpacing the Zacks Consensus Estimate marginally and rising 9.9% on a year-over-year basis. Total revenues of $4 billion surpassed the consensus estimate by a slight margin and grew 2.3% from the year-ago quarter.
The IQV stock has declined 10.5% over the past six months against the 9.8% rally of the industry it belongs to and 17.4% growth of the Zacks S&P 500 Composite.
IQVIA Holdings Inc. Price, Consensus and EPS Surprise
IQVIA Holdings Inc. price-consensus-eps-surprise-chart | IQVIA Holdings Inc. Quote
IQVIA’s Quarterly Details
The Research and Development segment’s revenues were $2.1 billion, increasing 1.3% from the year-ago quarter and 1% on a constant-currency basis. This metric missed our estimate of $2.2 billion and increased 9.5% on a constant-currency basis.
Revenues from the Technology and Analytics segment were $1.7 billion, growing 8.3% from the year-ago quarter and 9.5% on a constant-currency basis. The metric beat our estimate of $1.6 billion and increased 10.6% on a constant-currency basis.
Contract Sales & Medical Solutions revenues decreased 4.8% on a year-over-year basis to $177 million and increased 3.2% on a constant-currency basis. The metric missed our projection of $187 million and declined 11.1% on a constant-currency basis.
Adjusted EBITDA for the fourth quarter of 2024 was $996 million, indicating a 3.1% rise from the year-ago quarter and lagging our projection of $1 billion.
The company exited the quarter with cash and cash equivalents of $1.7 billion compared with $1.6 billion at the end of the preceding quarter. Long-term debt (less current portion) was $12.8 billion compared with $12.3 billion at the end of the third quarter of 2024.
Net cash generated from operating activities was $885 million and the capital expenditure for the quarter was $164 million. The company generated a free cash flow of $721 million in the quarter.
IQV’s 2025 Guidance
For 2025, IQVIA has raised its revenue guidance to $15.72-$16.12 billion from the preceding quarter’s view of $15.35-$15.40 billion. The mid-point ($15.92 billion) of the guided range is lower than the Zacks Consensus Estimate for revenues pegged at $16.02 billion.
The company has hiked the adjusted EPS guidance to $11.70-$12.10 from the previous quarter’s view of $11.10-$11.20. The mid-point ($11.9) of the guided range is higher than the Zacks Consensus Estimate for earnings pegged at $11.8 per share.
The company’s adjusted EBITDA view for the same period has been raised to $3.76-$3.88 billion compared with the preceding quarter’s view of $3.67-$3.70 billion.
IQV carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Earnings Snapshot
Gartner, Inc. (IT - Free Report) reported better-than-expected fourth-quarter 2024 results.
IT’s adjusted earnings per share of $5.6 beat the Zacks Consensus Estimate by 69.3% and increased 79.3% from the year-ago quarter. Revenues of $1.7 billion surpassed the consensus estimate by 1.8% and improved 8.2% year over year.
Broadridge Financial Solutions, Inc. (BR - Free Report) posted impressive second-quarter fiscal 2025 results.
BR’s adjusted earnings of $1.6 per share outpaced the consensus mark by 12.2% and increased 69.6% from the year-ago quarter. Total revenues of $1.6 billion surpassed the consensus mark by 3% and rose 12.8% year over year.